Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 13/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964089 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL17871701 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL31388217 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL31128130 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL442668 | 1.00 | MC4R (0.54) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| Hydrochloric Acid SCHEMBL17871800 | 0.98 | MC4R (0.53) | MC4RKEAP1CYP3A4GAAMAPK1 | |
| SCHEMBL5792053 | 0.98 | MC4R (0.55) | MC4RKEAP1CYP3A4GAAKCNQ2 | |
| Methylene Chloride SCHEMBL27881490 | 0.95 | MC4R (0.54) | MC4RKEAP1CYP3A4GAA | |
| SCHEMBL19665213 | 0.88 | KEAP1 (0.45) | MC4RKEAP1GAAMAPK1KCNQ2 | |
| Glutarate SCHEMBL2343643 | 0.87 | MC4R (0.53) | MC4RCYP3A4GAAKCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105384708-A | Preparation method for (S)-(+)-1-(2-piperidine phenyl)-3-methyl n-butylamine | Henan purui pharmaceutical co ltd | 2016-03-09 | — | — | CN | claimed |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2012-03-15 | — | — | US | claimed |
| US-8101769-B2 | Chemical intermediate; high purity drug | ACTAVIS GROUP PTC EHF (IE) | 2012-01-24 | — | — | US | claimed |
| EP-2358369-A1 | Process for the preparation of substantially optically pure repaglinide and precursors thereof | Krka Tovarna Zdravil, D.D., Novo Mesto (SI) | 2011-08-24 | — | — | EP | claimed |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | ACTAVIS GROUP PTC EHF (IS) | 2010-08-05 | — | — | US | claimed |
| WO-2010046360-A1 | PROCESS FOR THE PREPARATION OF SUBSTANTIALLY OPTICALLY PURE REPAGLINIDE AND PRECURSORS THEREOF | KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO (SI) | 2010-04-29 | — | — | WO | claimed |
| EP-2019097-A1 | Process for preparing (alphaS)-alpha-(2-methylpropyl)-2-(1-piperidinyl)benzenemethanamine | Aurobindo Pharma Limited (IN) | 2009-01-28 | — | — | EP | claimed |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | ACTAVIS GROUP PTC HF (IS) | 2008-08-21 | — | — | US | claimed |
| US-7041830-B2 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-05-09 | — | — | US | claimed |
| US-20040192921-A1 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2004-09-30 | — | — | US | claimed |
| EP-0965591-B1 | Process for the preparation of (S)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-09-04 | — | — | EP | claimed |
| EP-0965591-A1 | (s)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine, its salts, synthesis and use in the long term therapy of diabetes mellitus | Boehringer Ingelheim Pharma KG (DE) | 1999-12-22 | — | — | EP | claimed |
| EP-3214077-B1 | PROCESS FOR THE PURIFICATION OF A PHARMACEUTICAL AGENT | ZAKL FARMACEUTYCZNE POLPHARMA S A (PL) | 2020-03-11 | — | — | EP | disclosed |
| CN-105384708-A | Preparation method for (S)-(+)-1-(2-piperidine phenyl)-3-methyl n-butylamine | Henan purui pharmaceutical co ltd | 2016-03-09 | — | — | CN | disclosed |
| CN-105198838-A | Preparation method of repaglinide | Henan purui pharmaceutical co ltd | 2015-12-30 | — | — | CN | disclosed |
| CN-105175361-A | Improved production process for repaglinide | TIANJIN PHARMACEUTICAL GROUP GENCOM PHARMACEUTICAL | 2015-12-23 | — | — | CN | disclosed |
| EP-0965591-A1 | (s)-3-methyl-1-(2-piperidino-phenyl)-1-butylamine, its salts, synthesis and use in the long term therapy of diabetes mellitus | Boehringer Ingelheim Pharma KG (DE) | 1999-12-22 | — | — | EP | disclosed |
| EP-0589874-B1 | USE OF (S)(+)-2-ETHOXY-4-[N-[1-(2-PIPERIDINOPHENYL)-3-METHYL-1-BUTYL]AMINOCARBONYLMETHYL]BENZOIC ACID FOR THE PREPARATION OF A LONGLASTING ANTIDIABETIC MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-09-08 | — | — | EP | disclosed |
| US-5312924-A | Compounds for lowering blood sugar and effecting metabolism | DR. KARL THOMAE GMBH (DE) | 1994-05-17 | — | — | US | disclosed |
| US-5216167-A | Hypoglycemic agents | DR. KARL THOMAE GMBH (DE) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192921-A1 | Process for preparing (RS) 3-methyl-1-(2-piperidinyl phenyl) butyl amine | GPR119, GLP1R, IRS1 | MC4R 274/4885KEAP1 1440/4885CYP3A4 72/4885 |
| US-20100197732-A1 | Repaglinide Substantially Free of Dimer Impurity | EMG1, DAP3, DRD4 | MC4R 1094/4885KEAP1 4787/4885CYP3A4 207/4885 |
| US-20120065404-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | MC4R 1174/4885KEAP1 3417/4885CYP3A4 55/4885 |
| US-20080200684-A1 | Process for Preparing Ethyl (s)-2-Ethoxy-4-[N-[1-(2-Piperidinophenyl)-3-Methyl-1-Butyl]Aminocarbonyl Methyl]Benzoate and Use Thereof for the Preparation of Repaglinide | MEP1B, GABRE, BPGM | MC4R 1174/4885KEAP1 3417/4885CYP3A4 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.